Skip to content

B&B PHARMA

Active Risk: not assessed
Private limited companyfounded 2014active for 12 yearsBlarenveld 18, 1650 Beersel, BelgiumKBO/BCE: BE 0554.988.666

Acts, filings and financial milestones

Deadline for the 2026 accounts: 31-07-2027
2026
05-10
NBB filing Annual accounts 2025 filedNBB
abbreviated format · 66 days late
2025
11-12
Gazette deed Reappointments: BALTHAZAR Emmanuel (director) and BOULAL Nassima (director)
Registered office clause: Blarenveld 18, 1650 Beersel4 points ▸
  • General meeting, 19-12-2023
  • Director reappointment, BALTHAZAR Emmanuel (director (not named in the articles))
  • Director reappointment, BOULAL Nassima (director (not named in the articles))
  • Registered office clause, Blarenveld 18, 1650 Beersel
  • The act holds 4 more points.

Open the act in the Belgian Official Gazette

19-08
NBB filing Annual accounts 2024 filedPDF
full format · 19 days late
2024
29-08
NBB filing Annual accounts 2023 filedPDF
full format · 29 days late
23-04
Gazette deed 2 directors resigning, 2 reappointed
Resignations: BALTHAZAR Emmanuel (manager) and BOULAL Sandra (manager) · Reappointments: BALTHAZAR Emmanuel (director) and BOULAL Sandra (director) · Registered office clause: Blarenveld nummer 18, 1650 Beersel7 points ▸
  • Director resignation, BALTHAZAR Emmanuel (manager)
  • Director resignation, BOULAL Sandra (manager)
  • Director reappointment, BALTHAZAR Emmanuel (director (not named in the articles))
  • Director reappointment, BOULAL Sandra (director (not named in the articles))
  • Registered office clause, Blarenveld nummer 18, 1650 Beersel
  • General meeting, 19-12-2023
  • 1,000 shares
  • The act holds 5 more points.

Open the act in the Belgian Official Gazette

2023
31-12
Financial Highest result from 2018 to 2025net €341,495 ▲102%
The operating result of €348,168 and the net result of €341,495 are both a record.
31-12
Financial Liquidity more than 5 timescurrent ratio 1.09
The current ratio rises from 0.22 to 1.09. Short-term debt falls from €361,625 to €119,598.
31-12
Financial Equity above €200,000equity €382,011 ▲843%
After 5 profitable years in a row, equity reaches €382,011.
06-08
NBB filing Annual accounts 2022 filedPDF
abbreviated format · 6 days late
2022
13-07
NBB filing Annual accounts 2021 filedPDF
abbreviated format · 18 days before the deadline
2021
02-07
NBB filing Annual accounts 2020 filedPDF
full format · 29 days before the deadline
2020
07-07
NBB filing Annual accounts 2019 filedPDF
micro format · 24 days before the deadline
Show earlier events
2019
31-12
Financial Back to profitnet €50,933
The net result is €50,933, after one loss-making year.
31-12
Financial Equity above €100,000equity €139,264 ▲51.5%
Equity rises from €91,931 to €139,264.
28-08
NBB filing Annual accounts 2018 filedPDF
full format · 28 days late
2018
31-07
NBB filing Annual accounts 2017 filedPDF
full format · on the deadline day
2017
30-08
NBB filing Annual accounts 2016 filedPDF
full format · 30 days late
2014
04-07
Gazette deed IncorporationPDF
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.

Sources:Publications in the Belgian Official GazetteFilings with the National Bank

History

B&B PHARMA was incorporated on 2 July 2014.1 Total assets fell from €910,288 in 2018 to €811,436 in 2025.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2018 and 2025

Next steps